A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with = 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN1 mi ypN1-3) after Neoadjuvant Chemotherapy

Brief description of study

The primary purpose of the study is to determine the safety and effectiveness of whether or not the use of experimental drug MK-3475 (pembrolizumab) along with the standard approach (no more treatment or additional chemotherapy and radiation therapy after surgery or radiation therapy alone after surgery) affect the treatment outcomes. Pembrolizumab is an experimental drug in this study, which means this drug has been tested in the laboratory and has been approved by the US FDA for testing in people. We want to know if MK-3475 (pembrolizumab) is better, the same, or worse than the standard approach alone.


Clinical Study Identifier: s18-01728
ClinicalTrials.gov Identifier: NCT02954874
Principal Investigator: Nina D'Abreo.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.